RT Journal Article
T1 Circulating myeloid-derived suppressor cells and regulatory T cells as immunological biomarkers in refractory/relapsed diffuse large B-cell lymphoma: translational results from the R2-GDP-GOTEL trial.
A1 Jimenez-Cortegana, Carlos
A1 Palazon-Carrion, Natalia
A1 Martin Garcia-Sancho, Alejandro
A1 Nogales-Fernandez, Esteban
A1 Carnicero-Gonzalez, Fernando
A1 Rios-Herranz, Eduardo
A1 de la Cruz-Vicente, Fatima
A1 Rodriguez-Garcia, Guillermo
A1 Fernandez-Alvarez, Ruben
A1 Rueda Dominguez, Antonio
A1 Casanova-Espinosa, Maria
A1 Martinez-Banaclocha, Natividad
A1 Guma-Padro, Josep
A1 Gomez-Codina, Jose
A1 Labrador, Jorge
A1 Salar-Silvestre, Antonio
A1 Rodriguez-Abreu, Delvys
A1 Galvez-Carvajal, Laura
A1 Provencio, Mariano
A1 Sanchez-Beato, Margarita
A1 Guirado-Risueño, Maria
A1 Espejo-Garcia, Pablo
A1 Lejeune, Marylene
A1 Alvaro, Tomas
A1 Sanchez-Margalet, Victor
A1 de la Cruz-Merino, Luis
K1 Cellular
K1 Biomarkers
K1 Immunity
K1 Immunomodulation
K1 Immunotherapy
K1 Myeloid-derived suppressor cells
K1 Tumor
K1 Área de Gestión Sanitaria Sur de Sevilla
AB The search for immunological markers with ability of predicting clinical outcome is a priority in lymphomas, and in cancer in general. It is well known that some immunomodulatory cells, such as myeloid derived suppressor cells (MDSCs) or regulatory T cells (Tregs), are recruited by tumors, jeopardizing antitumor immunosurveillance. In this work, we have studied blood levels of these immunosuppressive cells in patients with relapsed/refractory diffuse large B-cell lymphoma (R/R DLBCL), prior to and along the course of the experimental rituximab, gemcitabine, dexamethasone, and cisplatin (R2-GDP) schedule, as a translational substudy of the R2-GDP-GOTEL trial (EudraCT Number: 2014-001620-29), which included lenalidomide as an immunomodulator. Blood samples were taken before treatment, at cycle 3 and end of induction. Samples were analyzed by flow cytometry. Non-parametric tests were used. Mann-Whitney U test was used to compare basal cells distributions, and Wilcoxon test was considered to compare cells distribution at different times. Spearman test was performed to measure the degree of association between cell populations. In this study, MDSC and Treg circulating concentration was found increased in all patients compared with a healthy control group and decreased after treatment only in patients with longest overall survival (>24 months), reaching the levels of the healthy group. Likewise, the number of inhibited T lymphocytes expressing Programmed Death-1 (PD-1) were increased in peripheral blood from patients and decreased on the treatment, whereas activated T lymphocytes increased after therapy in those with better overall survival. In conclusion, blood concentration of MDSCs and Treg cells may be good prognostic markers for overall survival after 2 years in R/R DLBCL. These results point to a possible role of these elements in the immunosuppression of these patients, as assessed by the circulating activated and inhibited T lymphocytes, and therefore, they may be considered as therapeutic targets in DLBCL.
PB BMJ Group
YR 2021
FD 2021-05-08
LK http://hdl.handle.net/10668/18034
UL http://hdl.handle.net/10668/18034
LA en
NO Jiménez-Cortegana C, Palazón-Carrión N, Martin Garcia-Sancho A, Nogales-Fernandez E, Carnicero-González F, Ríos-Herranz E, et al. Circulating myeloid-derived suppressor cells and regulatory T cells as immunological biomarkers in refractory/relapsed diffuse large B-cell lymphoma: translational results from the R2-GDP-GOTEL trial. J Immunother Cancer. 2021 Jun;9(6):e002323
NO We thank the patients and their families for their commitment and the persons from the healthy cohort for their voluntariness. We also want to thank to Rosso- Fernández Clara M. and Borreguero Borreguero I. from the CTU- HUVR; Clinical Trials Unit, Hospital Universitario Virgen del Rocío. Spanish Clinical Research and Clinical Trials Platform (SCReN,PT13/PT17/0017/0012). Finally, we want to acknowledge the help and compromise of Armando Ortega Cejas (former Celgene medical advisor).
DS RISalud
RD Apr 7, 2025